Skip to main content

Table 3 Haplotype of CpG sites between CAD patients and controls (%)

From: A preliminary study showing no association between methylation levels of C3 gene promoter and the risk of CAD

Haplotype

Depth

CAD (%)

Control (%)

P

CCCC

79,034

49.2 ± 5.9

47.8 ± 7.2

0.135

TTTT

60,288

34.2 ± 6.6

35.4 ± 7.6

0.179

TCCC

5947

3.6 ± 1.2

3.8 ± 2.3

0.671

TTCT

4449

2.5 ± 0.8

2.6 ± 0.8

0.358

CTCC

4221

2.7 ± 0.9

2.6 ± 0.9

0.283

CCCT

3688

2.3 ± 1.0

2.2 ± 0.7

0.890

CCTC

3666

2.3 ± 0.7

2.3 ± 0.7

0.772

  1. CAD coronary artery disease